Condition: Immunoglobulin A Nephropathy (IgAN) · Complement 3 Glomerulopathy (C3G) · IC-MPGN · Sponsor: ADARx Pharmaceuticals, Inc.
This is a Phase 2 study to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics of ADX-038 in adults with complement-mediated kidney diseases. The study will enroll Chinese adults with IgA nephropathy, complement 3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN). The study will evaluate ADX-038 administered alone (Part A) and in combination with telitacicept (Part B).
This description comes directly from the study's public registry record.
Stephanie Leyva · 877-232-7974 · info@adarx.com
Always discuss trial participation with your own doctor first.
| ADARx Clinical Site | Shenzhen, Guangdong, China | Recruiting |
| ADARx Clinical Site | Guiyang, Guizhou, China | Recruiting |
| ADARx Clinical Site | Zhengzhou, Henan, China | Not Yet Recruiting |
| ADARx Clinical Site | Baotou, Inner Mongolia, China | Recruiting |
| ADARx Clinical Site | Wuxi, Jiangsu, China | Recruiting |
| ADARx Clinical Site | Yantai, Shandong, China | Recruiting |
| ADARx Clinical Site | Beijing, China | Recruiting |
| ADARx Clinical Site | Shandong, China | Recruiting |
| ADARx Clinical Site | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07522099